Phase II Randomized Double-Blinded Placebo-Controlled study that will evaluate the efficacy safety and tolerability of natalizumab as adjunctive therapy in adult subjects with drug-resistant focal epilepsy.
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Epilepsy
-
Age: Between 18 - 75 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Subjects who are prescribed Brivaracetam (BRV)
- Subjects who are able to complete and sign the informed consent form
- Subjects who can understand and complete study questionnaires
- Subjects who have never been treated with BRV or first-ever treatment with BRV has been initiated within the prior 2 days
- Subjects who have a history of focal (partial) seizures.
- Subjects who are receiving more that 1 antiepileptic drugs (AEDs)
- Subjects have previously or currently using Levetiracetam (LEV), Oxcarbazepine (OXC), Carbamazepine (CBZ), and/or Lamotrigine (LTG)
- Subjects must be at least 16 years old
- Subjects diagnosed with epilepsy for at least 1 year
You may not be eligible for this study if the following are true:
-
- Subjects with nonepileptic seizures with or without comorbid epileptic seizures.
- Subjects suspected of having alcohol or drug-related seizures.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.